SKIN AND NAIL COMPOSITION CONTAINING PHOSPHATE-TRIALKANOLAMINE COMPLEX

Abstract: Topical medicaments and skin and nail preparations which comprise a phosphatide component (a) and an ethanolamine component (b). In the skin and nail embodiments there is no necessity for any additional third component, although additional ingredients may be included. In the topical medicament embodiment, there are three components, the invention as to topical medicaments being a preparation for application to the skin of a patient which contains a drug capable of passing through said skin to provide topical relief to said patient for the purpose for which said drug is administered, said topical medicament comprising a mixture of: (a) at least about 1% by weight of a lecithin-containing phosphatide, the amount of lecithin in said phosphatide being about 10% to about 40% by weight; (b) at least about 0-2% by weight triethanolamine; and (c) a drug suitable for topical administration, said topical medicament providing said drug suitable for topical administration in a form to permit retention of said drug at the skin of said patient to whom said drug being applied and protecting the skin area due to the presence of a complex of the components (a) and (b).

Description: SKIN AND NAIL COMPOSITION CONTAINING PHOSPHATE- TRIALKANOLAMINE COMPLEX TOPICAL MEDICAMENT 1 The present invention provides a topical mode of applying drugs, including steroids and also drugs to clear up or prevent local skin conditions such as eczema. Critical to the present invention is the combination of the drug with a phosphatide that includes lecithin. In one preferred embodiment, triethanolamine is also included. In the skin preparation of the present invention the drugs are retained for a long period of time, permitting a pro ¬ longed dispersal of the drug. The phosphatides which can be used in the skin prepa- tion of ' this invention include phosphatidyl choline (lecithin) , phosphatidyl ethanolamine (cephalin) , phospha¬ tidyl serine, phosphatidyl inositol and phosphatidic acid. A mixture of the above phosphatides can also be used. Optimally the phosphatide should contain 10 to 40% lecithin. It is advantageous to use a commercially available lecithin containing a phosphatide mixture and especially soy phosphatide (soy lecithin and egg phosphatide (egg lecithin) as the mixture of the phosphatides. Such commercially available phosphatides contain various phosphatides and other components. The amount of the phosphatides which are used in the skin preparation of this invention varies with the condi ¬ tion or symptom to be treated, the formulation, and the kind and amount of the topically delivered drugs contained in the skin preparation. However, the amount of the phos¬ phatides is normally in the range of 0.5 ot 8% by weight, and preferably 1.5 to 5% by weight. If the phosphatide is used in too small amounts, the beneficial effects of this invention will be insufficient. The effect of the skin preparation attained when the phosphatide is used in an excessive amount is not proportional to the amount of the phosphatide to be used, because the skin cannot < - absorb the excessive amount of the phosphatide. In addition, the use of the excessive phosphatides causes stickiness. Therefore, in general, a not more than 5% composition will be satisfactory. While in the generic aspect of the invention lecithin may be used by itself with drug, in on embodiment trial- kanolamines are used that may complex with the lecithin. Particularly, substituted and hindered trialkanolamines are considered such as triethanolamine and triisopropan- olamine. The alkanolamine can be used in an amount of 0.2 to 25 moles per mole of the phosphatide, preferably 1 to 10 moles, and more preferably 1.5 to 5 moles are used. Depending upon the intended use of the skin prepa¬ ration of this invention, other components can be incor¬ porated into the skin preparation of this invention to prepare the skin preparation having various rheological properties. For such formulations there can be used an aqueous mixture such as- a solution, colloidal solution, emulsified lotion, oil-in-water cream (hydrophilic cream) and aqueous gel wherein the aqueous phase is the continuous one. For such formulations, there can also be used an oily mixture such as a solution, ointment, water-in-oil cream, gel base (e.g. Plastibase, a polyethylene and liquid petrolatum base) , absorption base and hydrophilic ointment wherein the oil phase is the continuous one and a nonaqueous water-soluble base such as a mixture of polyethylene glycol. Such water-in-oil formulations are especially useful in preventing transdermal water loss and serve as effective carriers for transdermal drug delivery. A suspension base such as a shaking lotion, in which a solid dispersing agent is added, can also be prepared. Oily components, emulsifiers, dispersing agents, r gelatinizers and solid materials which can be used to prepare such formulations are well known, as those used are in the preparation of cosmetics and topical products. The oily components include hydrocarbons such as liquid paraffin, petrolatum, solid paraffin, microcrys- talline wax and the like; higher aliphatic alcolhols such as cetyl alcohol, hexadecyl alcohol, stearyl alcohol, oleyl alcohol and the like, esters of higher aliphatic alcohols such as bees wax, spermaceti and the like; esters of higher aliphatic acids with lower alcohols such as isopropyl myristate, isopropyl palmitate and the like, vegetable oils, modified vegetable oils, anhydrous lanolin and its derivative, squalene, squalane and the like. Higher aliphatic acids such as plamitic acid, stearic acid and the like can also be used. However, they should be used in a smaller amount, since they form a soap with alkanolamine. Useful emulsifiers and dispersing agents include anionic, cationic and nonionic surfactants. Nonionic surfactants are preferred because of their low level of irritation to skin. Typical of nonionic surfactants are monoglycerides such as glyceryl monostearate and the like; sorbitan aliphatic esters such as sorbitan mono- laurate and the like; sucrose aliphatic esters; polyoxyethylene aliphatic esters such as polyoxyethylene stearate; and polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene fatty ethers and the like. Gelatinizers include carboxymethylcellulose, cellu¬ lose gel, carbopol (carboxypolymeth lene) , polyvinyl alcohol, polyethylene glycol and various gums. These oily components, emulsifiers, dispersing agents and gelatinizers can be used alone or in combina¬ tion with each other. The incorporation into the skin preparation of this invention of propylene glycol, glycerine, sorbitol or the like which have moisturizing action is preferred, because it enhances moisturizing action of the skin preparation of this invention. Ethanol may be provided as a component of the skin composition, ethanol having bacteriostatic action and providing a cooling effect upon application to the skin. In order to increase the stability of the skin prepa¬ ration of this invention and/or the drugs contained therein, it is preferred to add antioxidants, chelating agents, antiseptics and the like, if necessary. The antioxidants include butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, sodium pyrosulfite, acetone sodium bisulfate and the like. The chelating agents include ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, thioglycerol and the like. The suitable antiseptics include methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid, o-phenylphenol, dehydroacetic acid and the salts thereof, p-chloro-m-cresol, p-chloro-m-xylenol and the like. In addition, it is preferred to adjust the pH of the skin preparation of this invention by adding citric acid, lactic acid, tartaric acid or the like. -The pH value which should be adjusted to is dependent upon the stability of the skin preparation. In general, it is preferred that the skin preparation be slightly acidic to slightly alkaline. A fragrance may be added in a slight amount, if desired. When the skin preparation of this invention is used for the delivery of drugs, the action of the drugs is strengthened, because the dispersion and retention in the skin of the drugs are enhanced to a considerable extent and pressure of the drugs maintained for a long period of time. Thus in the case of many steriods there appears to occur a complexing with the phosphatide " causing uniform distribution and release over the skin surface. Any drugs which are applicable to the skin can be used in the skin preparation of this invention. Examples of such drugs are topical steroid hormones such as hydrocortisone, prednisolone, methylprednisolone, dexamethasone, triamcinolone, triamcinolone acetonide, flumethasone, fluocinonide, beclomethasone, betamethasone, fluocinolone, fluorometholone, fludoxycortid, clometasone, clobetazol and their esters. Other drugs which can be applied to the skin prepa¬ ration of this invention include topical antibiotics such as kanamycin, erythromycin, tetracycline, gentamycin, fradiomycin, chloramphenicol and their salts; anti-mucotic agents such as griseofulvin, siccanin, trichomycin, nystatin, silver sulfadiazine, and the like; topical sulfa drugs such as sulfisoxazole and the like; topical antihistamines such as diphenhydramine, chlorphenilamine and the like; local anesthetics such as lidocaine, dibucaine, cyproheptazine and cocaine; non-steroidal antiinflammatory agents such as indomethacin, diflumidone, bufexa ac and the like; anticoagulants such as heparin sodium; skin keratolytic agents such as urea, salicylic acid, resocinol, coal tar, anthralin and the like; agents affecting pigmentation such as methozalen and the likes; vitamins such as vitamin A, vitamin E and the like; sex hormones such as ethinyl estradiol, testosterone, progesterone and the like; antianginal drugs such as isosorbide dinitrate, nitroglycerin, verapamil, prenil- amine and the like; beta-blocking agents such as propanolol, pindolol, aiprenolol and the like; antihyper- tensive agents such as fydralazine, reserpine, clonidine and the like and bronchodilators such as isoproterenol, meta-proterenol and the like; antiallergic agents such ascromolyn sodium and the like and antiserotonergic agents such as cyproheptazine. The opical steroid hormone can be applied in combi¬ nation with one or more drugs of topical anticiotics, antihistaminics and anti ycotic agents. Anticancer drugs such as tetrahydrofluorouracil, fluorouracil, bleomycin, mitomycin and the like can also be applied to the skin preparation of this invention. The amount of the .drugs to be added to the skin preparation should be determined on the basis of the activity of the drugs. When a larger amount of the drug is used, it is preferred to increase the amounts of the phosphatide and the alkanolamine to be used. A drug can be added to the skin preparation either in the form of a solution in the oily components, water, propylene glycol, polyethylene glycol or ethanol, or in the form of a solid as it is or as pulverized powder. The symptoms of patients with dry skin condition disappear or are alleviated by application of the skin preparation of this invention. The skin preparation of this invention containing a topical steriod hormone can be used to treat eczema, ichthyosis, lichen psoriasis and the like to attain the disappearance or alleviation of the sympton. As described above, the skin preparation of this invention has the action of moisturizing and tenderizing skin and nail. In addition, the skin preparation of the invention, when used for the delivery of drugs, disperses and retains the drugs in the skin in a uniform manner. Therefore, the skin preparation of this invention is very useful for moisturizing skin, preventing keratinization, tenderizing nail and treating skin diseases. Beyond the general description of this invention, a more complete understanding can be obtained by examples which are provided herein for purposes of illustration only and are not intended to be limiting in any manner. A. OLEAGINOUS OINTMENT (A-l) Ointments prepared from petrolatum White petrolatum was melted on a water bath and warmed to about 70°C. The other ingredients were dispersed in the liquid paraffin and wnrmed to 70 β C and then added to the petrolatum and v/as stirred until it congealed. (A-2) Ointments prepared from Plastibase All of the components are combined and stirred to obtain a uniform mixture. B. POLYETHYLENE GLYCOL OINTMENT Polyethylene glycol 400 was heated on a water bath at 60 to 70°C. Polyethylene glycol 400 and the other ingredients, previously dispersed in the liquid paraffin, were added to this melt with stirring. Stirring was continued until the soli ification takes place. C. ABSORPTION OINTMENT Cetyl alcohol and white petrolatum were melted on a water bath, .then the other ingredients were added to this melt and the mixture was heated to about 75°C wi h stirring. Next, the de ionized water was heated to the same temperature and added. The • mixture was stirred until it congealed. D. OIL-IN-WATER CREAM (HYDROPHILIC OINTIE T) Stearyl alcohol, cetyl alcohol, polyoxyethylene 45 monostearate and white petrolatum were melted on a water bath, then the other ingredients were added to this melt and the mixture was heated to about 75°C with stirring. Next, the deionized water was heated to the same temperature and added. The mixture was stirred until it congealed. .1 Example 1 Oil-In-Water Cream The following skin preparation was made: White petrolatum 9.9% by weig liquid paraffin • 12.9 stearyl alcohol 5.0 Cetyl alcohol 2.1 SLP-White (powdery soy 4.0 lecithin having a phos¬ phatide content of 95%) Triethanolamine 0 .8 Citric acid monohydrate 0 , . 35 Dibutyl hydroxytoluene 0 , . 025 Polyoxyethylene 1000 cetyl ether 4 , .0 -Ch1oro-m-creso1 0 , . 2 Deionized water r ema i n der 100% The above skin preparation has been tested on the skin a found to provide a good moisturizing effect. The moistu barrier provided by the relatively large molecular compl (each mole of lecithin capable of complexing tightly wit to 12 molecules of water) and the lecithin staying near surface due to the positively and negatively charged portions of the molecule, the skin preparation of the present invention provides relatively long protection fo the skin against drying. Varying the ratio of triethanolamino to a phosphatide, tests have been made. Most advantageous effects have been found for 1 to 4 mol of triethanola fne per mole of a phosphatide. - EXAMPLES 2 to 5 The following skin preparations were made: Polyethylene o/w Oleaginous Glycol Absorbtion Ointment Ointment Ointment cream EXAMPLE No. Composition 2 3 4 5 SLP-White (Soybean . lecithin) 4.0 4.0 4.0 4. Q . V Triisopropanolamine 1.0 1.0 1.0 1.0 . Lactic Acid 0.58 0.58 0.58 " 0.58 Butylated hydroxytoluene 0.025 0.025 0.025 0.025 White petrolatum 9.9 10.0 40.0 liquid paraffin 12.9 - - - Plastibase 50 W (polyethylene and liquid petrolatum base) 94.395 - Stearyl alcohol 5.0 - - - Cetyl alcohol 2.1 - - 18.0 Polyethylene glycol 4000 - 41.395 Sorbitan Sesquioleate - - - 5.0 Polyoxyethylene 45 Monostearate 4.0 - - - Polyoxyethylene lauryl ether - - - 0.5 p-Chloro-m-cresol 0.2 - - 0.2 Deionized water 60.745 - 30.695 Total (% by weight) 100.0 100.0 100.0 100.0 Using these skin preparations, transepidermal water loss experiments were made. I. Skin samples are obtained from fresh cadavers. All skin samples are from the abdominal area. Epidermis is separated from dermis by the procedure of Baumberger (J. of Natl. Cancer Inst. (US) 2_, 413, 1941) . Epidermal samples are wrapped in aluminum foil and are maintained at -20° until used. II. Apparatus for transepidermal water loss is all glass with ground glass joints to secure the epidermis. T opening in the apparatus over which the epidermis is placed occupied 2 cm 2. All of the apparatus is inside an analytical balance. The balance chamber contains a humidity controller. Weight measurements are made as a function of time. Epidermal samples, about 2 cm on a side, are placed onto the water reservoir portion of the TWL apparatus. The open cover of the apparatus is clipped into place with the epidermis clamped between the ground glass surfaces. The apparatus containing the epidermal sample and water is weighted. Thirty minutes are allowed for evaporation of surface water before measurements begin. Gravimetric measurements allow for determinations of water loss to be made. 2-4 hours are required for steady state to be achieved. Measurements continue for several hours after steady state has been achieved. The steady state rate at the 15th hour from the start of the measurement is used as the transdermal water loss rate. s / The followi ng skin preparations were used as references o/w Cream Oleaginous Oiπt eπt Comparative Skin Preparation A B C Compos it ion White petrolatim 9. .9 100 Liquid paraffin 12 .9 Plastibase 50W - 100 Stearyl alcohol 5, .0 Cetyl alcohol 2 .1 Polyoxyethylene cetyl ether 1\ .7 P-Chloro-M-Cresol 0. .1 Deionized water 68, .3 Total (% by weight) 100, .0 100.0 100.0 The results are shown in the following table: Skin Preparat i on the start of the experiment Untreated epidermal sample 0.49 lipid extracted material 1.0 carried out with CHCl 3 /MeOH Skin Preparation A - 0.44 It B 0.065 rt C 0.060 Skin Preparation 2 0.25 II 3 0.041 4 0.055 5 0.13 The transepidermal water loss (TWL) values represent averages of 3 sets of values carried out on 3 different samples of epidermal skin for each condition. The data obtained with lipid extracted material (carried out with chloroform-methanol) demonstrate that the water loss through epidermis is substantially enhanced. This indi¬ cates that the barrier to water loss by epidermis and by stratum corneum is substantially determined by lipid content. The untreated sample drops to a half value. The rate of epidermal water loss of the epidermal skin sample treated with the conventional skin preparation decreases as the water content of the skin preparation decreases. Although a decrease in the rate of epidermal water loss of the epidermal skin sample treated according to this invention is accompanied by a decrease in the water content of the skin preparation, the decrease is always smaller than that of the conventional skin prepa¬ ration compared at the smae water content. This demon¬ strates that phosphatide and triisopropanolamine containe in the skin preparation of this invention suppress the water loss. EXAMPLES 6, 6*, 6*', 7, 7', and 8: Topical steroid hormone skin preparations having the fol¬ lowing composition were prepared. The Toneli method was used to measure the anti-inflam¬ matory activity of this skin preparation [Endocrinology 77 625-634 (1965)]. A phlogistic solution comprising pyridine, ether and croton oil (50:45:5 V/V)) is applied to the right ear of the mouse and then the skin prepa¬ ration is applied thereon. Five hours after the treat¬ ment, both of the ears are excised at a predetermined position and the wet weight of the ears are determined to calculate the edema ratio according to the following equation: Weight of Right Ear Edema Ratio (%) = ( 1) x 100 Weight of Left Ear Inhibition ratio is calculated according to the following equation: Inhibition Ratio (%) Edema ratio when treated with ointment = (1 : ) x 100 Edema ratio when untreated Ten male mice weighing 20 to 25 g are used as one group. The results are shown in the following table. - 15 - Drug Preparation Edema Ratio Inhibition Effect* Ratio ' (%) Example 6 22.9 77.9 Becloπethasone Example 6 23.1 77.7 17, 21-dipropionate Comparative D 32.8 68.4 ++ Example 7 39.1 62.3 -H- Hydrocortisone Comparative E 45.1 56.5 -H- Example 8 35.7 65.5 -H- Prednisolone Comparative F 40.2 61.2 ++ Untreated 103.6 0 - Score Inhibition Ratio +++ 75-100% ++ 50-75% + 25-50% 0-25% As is apparent from the above table, the skin preparatio of this invention possesses higher anti-inflammatory activity as compared with the conventional ointment base Judging from these results, the pharmaceutical effects of the skin preparation of this invention are raised by the formation of a complex in which a phosphatide is non-convalently complexed with a steroid, because the complex increases the compatibility and retainability of the steroid in the skin. EXAMPLES 9, 10 and 10' The skin preparation having the following composition are prepared. Oleaginous o/ cream Absorption Ointment Oi ntment Example No. Example Compara- Example Co para- Example tive tive Composition (9) (G) (10) (H) (10') Hydrocortisone 17-butylate 0.1 0.1 Indomethacin - 1.0 1.0 1.0 SLP-Whi te • 4.0 4.0 4.0 (Soy lecithin) Tri isopro- panolamine . 1.0 1.0 1.0 Lactic acid 0.58 0.58 0.58 Butylated hydroxytoluene 0.02 0.025 0.025 White Petrolatum - 9.9 9.9 40.0 Liquid paraffin - 12-.9 12.9 Plastibase 50W 94.292 99.9 Stearyl alcohol 5.0 5.0 Cetyl alcohol 2.1 2.1 18.0 Polyoxyethylene 45-monos tearate 4.0 4.0 p-Chloro-m- eresol 0.2 0.2 0. 2 De ionized water qs qs 29 .695 Sorbi tan sesquioleate 5. 0 Polyoxyethylene lauryether 0. 5 Total (w/v,%) 100.0 100.0 100.0 100.0 100.0 ' c Anti-inflammatory activity is measured for the above skin preparations by skin carrageenan edema inhibition test. The test is conducted by the following method. Male rats weighing 190-210 g are used in the fol¬ lowing test. Their side abdominal hair is removed before the start of this test. 1% carrageenin solution is injected intra-dermally at a predetermined position from each side of the abdomen. Immediately after carrageenin injection, 1 ml of 1% pontamine sky blue saline is admin¬ istered intravenously.- Furthermore, an accurately deter¬ mined volume of topical formulation is applied on the surface of the abdominal skin. Five hours after the treatment, the abdominal skin is removed from the body and score as to the following items. Dye leakage at the injection site Calculated by measuring the maximum and minimum diameter of the dye blue spot. Edema skin weight Calculated by measuring the weight of the perforated edema skin (1cm x 1cm = round shape) Edema weight = Edema skin weight - Normal skin weigh Edema ratio = Edema weight / Normal skin weight The results are shown in the following table. Hydrocortisone 17-alpha-butyrate - 0.1% E amp1e Comparat ϊve Untreated (9) (G) Edema weight 58.4 72.9 111.7 (mg) (-47.7%) (-34.7%) . ( - ) Edema ratio 79.4 99.7 142.8 (-44.4%) (-30.2%) ( - ) Blue area 68.7 79.5 123.3 (rrm Z ) (-44.3%) (-35.5%) ( - ) Effect* ++ ++ Indomethacin 1% Example Comparative Untreated (10) (H) Edema weight 51.6 62.9 67.6 (mg) (-23.7%) (- 7.0%) ( - ) Edema ratio 68.9 " 86.9 90.8 (-24.1%) (- 4.3%) ( - ) Blue area 72.5 68.2 77.9 (mm 2 ) (- 6 ' .9%) (-12.5%) ( - ) Effect ' *Score ++ ■ Inhibition ratio 30-45% + 15-30% 0-15 As is apparent from the above table, the skin preparation of this invention possesses higher anti-inflaπmatory activity as compared with the conventioanl topical -fonnulations. / - ' "■ _. . EXAMPLES 11 and lϊ» - 20 - • The skin preparations having the following composition were prepared. • o/w cream Absorption Ointment Examp1e 11 - Example 11 Chlorpheniramine Maleate 1.0 % by weight 1.0 White petrolatum 9.9 . 40.0 Liquid paraffin 12.9 - Stearyl alcohol 5.0 - Cetyl alcohol 2.1 18.0 SLP-Whϊte (Soy lecithin) 4.0 4.0 . Tri ethanolamine 0.8 0.8 Citric acid " monohydrate 0.35 0.35 Butylated hydroxytoluene 0.025. 0.025 Polyoxyethylene 5-monosteara e 4.0 - p-Chloro-m-eresol 0.2 0.2 Deionized water qs 30.125 Sorbitan sesquioleat - 5.0 Polyoxyet ylene laurylether 0.5 Total (% by we ight) 100.0 100.0 The above skin preparation has been tested on the guinea- pig back skin and found to be more effective in preventin vascular permeability increase caused by 0.1% histamine 0.05 ml as compared with the conventional ointment bases. EXAMPLES 12-27 Skin preparations are prepared having the ■ composition shown in the following table : EXAMPLE NO , Example 12 Example 13 Example 14 Drug Sulfisoxazole Tetracycline Chloramphenicol Hydrochloride 5.0 3.0 2.0 S P - White (Soy Lecithin) 4.0 4.0 4.0 4.0 4.0 4.0 Triethanolamine 0.8 0.8 0.8 0.8 0.8 0.8 Triisopropanolamine Lactic acid 0.62 0.62 0.62 Citric acid - 0.35 0.35 0.35 Butylated hydroxytoluene 0.025 0.025 0.025 0.025 0.025 0. .025 White petrolatum 40.0 9.9 86.555 9.9 9. .9 Liquid paraffin - 12.9 5.0 12.9 12. .9 Plastibase 50W 92.555 Stearyl alcohol - 5.0 5.0 5. .0 Cetyl alcohol 18.0 2.1 2.1 2. .1 Polyethylene Glycol 4000 Polyethylene Glycol 400 Polyoxyethylene 45 monostearate - 4.0 4.0 4.0 Sorbitan sesquioleate 5.0 Polyoxythylene laurylether 0.5 p-Chloro-m^cresol 0.2 0.2 0.2 0.2 Deionized water 25.855 55.725 SI.125 58.725 Total (% by weight) 100.0 100.00 100.0 100.0 100.0 100.0 Type of Absorp- o/w olea- o/w olea- o/w Formulation tion cream ginuous cream ginuous cream - ointment ointment ointment EXAMPLE NO. Ex amp 1 e 15 Examp l e 16 E amD l e 17 Drug Gen tamϊ c in Acr ϊ sorc in I chthamπαol s ulfate 0.2 10.1 0.1 to 10.0 SLP - White (Soy lecithin). .4.0 4.0 4.0 4.0 4.0 Triethanolamine 0.8 0.8 Tri isopropanolamine 1.0 1.0 1.0 Lactic acid 0.62 0.58 0.58 Citric Aci * 0.35 0.32 Butylated hydroxytoluene 0.025 0.025 •0.025 0.025 0.025 White petrolaturrl - 9.9 40.0 9.9 79.395 Liquid paraffin • 10.0 I?.9 - 12 " .9 5.0 Plastibase 50W .- - - - - Stearyl alcohol - 5.0 - 5.0 - Cetyl alcohol - . 2.1 18.0 2.1 - Polyethylene Glycol. 4000 q- .s.-lOO — . — — _ Polyethylene Glycol 400 42.0 — — — _ Polyoxyethy1 ene 45 monostearate .-_ 4.0 ^ 4.0 Sorbitan .sesquioleate 5.0 Polyoxye ylene ■ laurylether σ.5 p-Chloro-m-cresol 0.2 0.2 0.2 Deionized water q.s.-100' ' q.s.-lOO q.s.-lOO Total (% by weight) " 100.0 100.0 100.0 100.0 100.0 Type of Po lyethyl- o/w Absorp- o/w Olea- Formulat i on ene glycol cream tionous creεm ginous o intment oi ntment o i n tmen t EXAMPLE NO. Example 18 Example 19 Example 20 Drug Undecylenic Nystatin Sodium Heparin Acid 5.0 and 0.4 Zinc ϋndecyle- (50,000 units) nate 20.0 SLP - White (Soy Lecithin) 4.0 4.0 4.0 4.0 Triethanolamine - - 0.8 0.8 Triisopropanolamine : 1.0 1.0 - - Lactic acid 0.58 0.58 0.62 Citric acid onohydrate _ - 0.35 Butylated hydroxytoluene 0.025 0.025 0.025 0.025 White petrolatum _ 40.0 9.9 Liquid paraffin 10.0 - 12.9 Plastibase 50W q.s.-lOO - - Stearyl alcohol - - 5.0 Cetyl alcohol _ _ 18.0 2.1 Polyethylene Glycol 4000 28.395 - - - Polyethylene Glycol 400 q.s.-lOO - - - Polyoxyethylene 45 monostearate - - - 4.0 Sorbitan sesquioleate - 5.0 - Polyoxyethylene - lauryl ether - - 0.5 - p-Chloro-m-cresol - - 0.2 0.2 Deionized water - - q.s.-lOO q.s.-lOO Total (5 by weight) 100.0100.0 100.0 100.0 Type of Polyethylene Oleaginous Absorption o/w Formulation glycol ointment ointment cream ointment ' - - EXAMPLE NO. Example 21 Example 22 Example 23 Drug Urea 5-Fl oro- Bleomycin 10.0 uracil sulf ate 5.0 0.5 SLP - White (Soy lecithin) 4.0 4.0 4.0 4.0 4.0 Triethanolamine Trϋsoproanolamine 1-0 1.0 1.0 1..0 1.0 Lactic acid 0.58 0.58 0.58 0.58 - Citric acid - - - - 0.32 Butylated hydroxytoluene 0.025 0.025 0.025 0.025 0.025 White petrolatum q.s.-lOO - 9.9 - 9.9 Liquid paraffin 5.0 - 12.9 10.0 12.9 Plastibase 50W - q.s.-lOO - - Stearyl alcohol 5.0 5.0 - 5.0 Cetyl alcohol 2.1 - 2.1 Polyethylene Glycol 4000 - - - 42.055 - Polyethylene Glycol 400 _ _ _ 42.0 - Polyoxyethylene 45 monostearate 4.0 - 4.0 Sorbitan sesquioleate - - - - - Polyoxyethylene lauryl ether - - - - - p-Chloro-m-cresol 0.2 - 0.2 Deionized water - - q.s.-lOO q.s.-lO Total (% by weight) 100.0 100.0 100.0 100.0 100.0 Type of Olea- Olea- o/w Poly- o/w Formulation ginous ginous cream glycol cream ointment ointment ointrrent (Soy lecithin) 4.0 4.0 4.0 4.0 4.0 4.0 Triethanolamine 0.8 0.8 0.8 0.8 0.8 0.8 Triisopropanolamine - _ - - - - Lactic acid 0.62 0.62 0.62 Citric Acid 0.35 0.35 - 0.35 .Butylated hydroxytoluene 0.025 0.025i 0.025 0.025 0.025 0.025 White petrolatum 86.555 9.9 89.545 9.9 — 9.9 Liquid paraffin ' 5.0 12.9 5.0 12.9 10.0 12.9 Plastibase 50W _ • _ - - - Stearyl alcohol' 5.0 5.0 ' - ' 5.0 Cetyl alcohol 2.1 2.1 - 2.1 Polyethylene Glycol 4000 - - - - 41.555 - Polyethylene Glycol 400 - - - - 42.0 - Polyoxyethylene 45 monostearate 4.0 4.0 - 4.0 Sorbitan sesquioleate - - - - - - Polyoxyethylene - • . lauryl ether - - - - - - p-Chloro-m-cresol 0.2 0.2 - 0.2 Deionized water q.s.-lOO q.s.-lOO — q.s.-lOO Total (% by weiqht) 100.0 100.0 100.0 100.0 100.0 100.0 Type of olecLginou≤ o/w olea- ό/w olea¬ o/w Formulation ointment cream ginous cream ginous cream ointment ointment EXAMPLE NO. Example 27 Drug Nitroglycerϊn 2.0 . SLP - White (Soy lecithin) 4.0 4.0 Triethanolamine 0.8 0.8 Triisopropanolamine Lactic acid 0.62 Citric Acid - 0.35 Butylated hydroxytoluene 0.025 0.025 White petrolatum 87.555 9.9 Liquid paraffin 5.0 12.9 Plastibase 50W Stearyl alcohol — 5.0 Cetyl alcohol — 2.1 Polyethylene Glycol 4000 _ ÷- Polyethylene Glycol 400 " - Polyoxyethylene 45 monostearate - 4.0 Sorbitan sesquϊoleate Pol oxyethylene lauryl ether p-Chloro-m-cresol — 0.2 Deϊonized water - 58.725 Total (% by wei ht) 100.0 100.0 Type of Oleaginous o/w Formulation ointment cream - r \ '

Claims: WHAT IS CLAIMED IS: 1. A topical medicament preparation for application to the skin of a patient which contains a drug capable of passing through said skin to provide topical relief to said patient for the purpose for which said drug is to be administered, said topical medicament comprising a mixture of: (a) at least about 1% by weight of a lecithin- containing phosphatide, the amount of lecithin in said phosphatide being about 10% to about 40% by weight; and (b) a drug suitable for topical administration, said topical medicament providing said drug suitable for topical administration in a form to permit retention of • said drug at the skin of said patient to whom said drug is being applied and protecting the skin area. 2. A topical medicament of claim 1 wherein said phosphatide is soy lecithin which contains a mixture of lecithin, other phosphatides and soy oil. 3. A topical medicament of claim 1 wherein said drug is a steroid hormone. 4. A topical medicament of claim 1 wherein said drug is a steroid hormone which is hyάrocortisone. 5. A topical medicament of claim 1 wherein said drug is a sulfadiazine. 6. A topical medicament of claim 1 wherein said drug is silver sulfadiazine. 7. A method of providing a prolonged topical application of a drug which comprises administering to the skin of a patient a topical medicament of claim 1, 2, 3, 4, 5 or 6.

Inventors: FREST P, KEITH A
Applicants: KEY PHARMA, KEY PHARMA INC
Application year: 1981
Main classification: A61K31
IPC codes: A61K8, A61K47, A61Q19